Venmax Drugs

{
  "main_header": {
    "sid": 225982,
    "name": "Venmax Drugs",
    "stock_name": "Venmax Drugs",
    "full_name": "Venmax Drugs & Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/venmax-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "28.40",
    "chg": 2.35,
    "chgp": "9.02%",
    "dir": 1,
    "prev_price": "26.05",
    "mcapval": "24.94 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531015,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE154G01022",
    "curr_date": "Apr 20",
    "curr_time": "",
    "bse_nse_vol": "92 ",
    "exc_status": "Active",
    "traded_date": "Apr 20, 2026",
    "traded_date_str": "2026 04 20",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/venmax-drugs-225982-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Venmax Drugs & Pharmaceuticals Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-venmax-drugs-pharmaceuticals-ltd-fallingrising-3848975",
        "imagepath": "",
        "date": "2026-02-21 01:00:00",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Price Movement and Market Comparison</strong></p>\n<p>Venmax Drugs’ recent price action has been notably weaker compared to the benchmark Sensex. Over the past week, the stock has declined by 3.67%, while the Sensex gained 0.23%. Similarly, in the last month, Venmax Drugs marginally fell by 0.46%, whereas the Sensex rose by 0.77%. This underperformance is further emphasised by the stock’s three-day consecutive fall, during which it lost approximately 4.7% of its value. Such a trend indicates a short-term bearish sentiment among investors.</p>\n<p>Despite these recent setbacks, the stock has delivered a positive return of 4.13% year-to-date, outperforming the Sensex which is down 2.82% in the same period. Over the last year, Venmax Drugs has appreciated by 6.96%, though this is sligh..."
      },
      {
        "title": "Venmax Drugs & Pharmaceuticals Downgraded to Strong Sell Amid Technical and Financial Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/venmax-drugs-pharmaceuticals-downgraded-to-strong-sell-amid-technical-and-financial-concerns-3843606",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenmaxDrugsPhar_mojoScore_3843606.png",
        "date": "2026-02-17 08:06:13",
        "description": "Venmax Drugs & Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Feb 2026, reflecting deteriorating technical indicators and stagnant financial performance. The company’s Mojo Score has slipped to 17.0, signalling heightened risk for investors amid a challenging market environment and weakening fundamentals."
      },
      {
        "title": "Venmax Drugs Falls 4.36%: 3 Key Factors Driving the Weekly Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/venmax-drugs-falls-436-3-key-factors-driving-the-weekly-decline-3841072",
        "imagepath": "",
        "date": "2026-02-15 13:00:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>09 Feb:</strong> Q3 FY26 results reveal revenue growth but wafer-thin margins and governance concerns</p>\n                    <p><strong>10 Feb:</strong> Quality grade downgraded to below average with a Sell rating assigned</p>\n                    <p><strong>10 Feb:</strong> Mixed technical signals emerge amid flat financial performance</p>\n                    <p><strong>13 Feb:</strong> Week closes at Rs.26.97, down 4.36%, underperforming Sensex</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.28.20</div></div>\n                    <div class=\"stat-item\">..."
      },
      {
        "title": "Venmax Drugs & Pharmaceuticals Ltd Downgraded to Sell Amidst Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/venmax-drugs-pharmaceuticals-ltd-downgraded-to-sell-amidst-mixed-financial-and-technical-signals-3829883",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenmaxDrugsPhar_mojoScore_3829883.png",
        "date": "2026-02-10 08:05:57",
        "description": "Venmax Drugs & Pharmaceuticals Ltd has been assigned a Sell rating with a Mojo Score of 33.0, reflecting a downgrade from its previous ungraded status. This change, effective from 09 Feb 2026, is driven by deteriorating quality metrics, challenging financial trends, and a cautious technical outlook, signalling increased risk for investors in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Venmax Drugs & Pharmaceuticals Ltd Quality Grade Downgrade: A Detailed Fundamental Analysis",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/venmax-drugs-pharmaceuticals-ltd-quality-grade-downgrade-a-detailed-fundamental-analysis-3829432",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenmaxDrugsPhar_qualitydot_3829432.png",
        "date": "2026-02-10 08:00:09",
        "description": "Venmax Drugs & Pharmaceuticals Ltd has recently undergone a significant downgrade in its quality grading, shifting from a non-rated status to a below average rating as of 9 February 2026. This change reflects a reassessment of the company’s core financial health and operational consistency, raising concerns about its long-term investment appeal despite some strong sales growth. This article delves into the key financial metrics and business fundamentals that have influenced this downgrade, providing investors with a comprehensive understanding of the company’s current standing within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Venmax Drugs Q3 FY26: Revenue Surge Masks Wafer-Thin Margins and Governance Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/venmax-drugs-q3-fy26-revenue-surge-masks-wafer-thin-margins-and-governance-concerns-3829125",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenmaxDrugsPhar_quaterlyResult_3829125.png",
        "date": "2026-02-07 23:45:37",
        "description": "Venmax Drugs & Pharmaceuticals Ltd., a micro-cap pharmaceutical company with a market capitalisation of just ₹25.00 crores, posted a net profit of ₹0.03 crores in Q3 FY26 (October-December 2025), marking a sequential increase of 50.00% from Q2 FY26's ₹0.02 crores. However, this modest absolute profit figure belies deeper structural concerns that continue to plague the Hyderabad-based company, including razor-thin operating margins, negative book value, and a dramatic decline in promoter holdings that has raised serious governance questions."
      }
    ],
    "total": 78,
    "sid": "225982",
    "stock_news_url": "https://www.marketsmojo.com/news/venmax-drugs-pharmaceuticals-225982"
  },
  "announcements": [
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "14-Apr-2026",
      "details": "Submission of Annual Secretarial Compliance Report for the year ended March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "14-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Venmax Drugs and Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1988PLC009102</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Priyanka Agarwal <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: venmaxdrugs@gmail.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Kummarikuntla Saibaba <br/> Designation: Chief Financial Officer <br/> EmailId: venmaxdrugs@gmail.com</div> </div> <div> <br/> Date: 14/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "14-Apr-2026",
      "details": "Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended March 31 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Venmax Drugs & Pharmaceuticals Ltd falling/rising?

2026-02-21 01:00:00

Short-Term Price Movement and Market Comparison

Venmax Drugs’ recent price action has been notably weaker compared to the benchmark Sensex. Over the past week, the stock has declined by 3.67%, while the Sensex gained 0.23%. Similarly, in the last month, Venmax Drugs marginally fell by 0.46%, whereas the Sensex rose by 0.77%. This underperformance is further emphasised by the stock’s three-day consecutive fall, during which it lost approximately 4.7% of its value. Such a trend indicates a short-term bearish sentiment among investors.

Despite these recent setbacks, the stock has delivered a positive return of 4.13% year-to-date, outperforming the Sensex which is down 2.82% in the same period. Over the last year, Venmax Drugs has appreciated by 6.96%, though this is sligh...

Read full news article

Venmax Drugs & Pharmaceuticals Downgraded to Strong Sell Amid Technical and Financial Concerns

2026-02-17 08:06:13

Venmax Drugs & Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Feb 2026, reflecting deteriorating technical indicators and stagnant financial performance. The company’s Mojo Score has slipped to 17.0, signalling heightened risk for investors amid a challenging market environment and weakening fundamentals.

Read full news article

Venmax Drugs Falls 4.36%: 3 Key Factors Driving the Weekly Decline

2026-02-15 13:00:06

Key Events This Week

09 Feb: Q3 FY26 results reveal revenue growth but wafer-thin margins and governance concerns

10 Feb: Quality grade downgraded to below average with a Sell rating assigned

10 Feb: Mixed technical signals emerge amid flat financial performance

13 Feb: Week closes at Rs.26.97, down 4.36%, underperforming Sensex

Week Open

Rs.28.20

...

Read full news article

Venmax Drugs & Pharmaceuticals Ltd Downgraded to Sell Amidst Mixed Financial and Technical Signals

2026-02-10 08:05:57

Venmax Drugs & Pharmaceuticals Ltd has been assigned a Sell rating with a Mojo Score of 33.0, reflecting a downgrade from its previous ungraded status. This change, effective from 09 Feb 2026, is driven by deteriorating quality metrics, challenging financial trends, and a cautious technical outlook, signalling increased risk for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article

Venmax Drugs & Pharmaceuticals Ltd Quality Grade Downgrade: A Detailed Fundamental Analysis

2026-02-10 08:00:09

Venmax Drugs & Pharmaceuticals Ltd has recently undergone a significant downgrade in its quality grading, shifting from a non-rated status to a below average rating as of 9 February 2026. This change reflects a reassessment of the company’s core financial health and operational consistency, raising concerns about its long-term investment appeal despite some strong sales growth. This article delves into the key financial metrics and business fundamentals that have influenced this downgrade, providing investors with a comprehensive understanding of the company’s current standing within the Pharmaceuticals & Biotechnology sector.

Read full news article

Venmax Drugs Q3 FY26: Revenue Surge Masks Wafer-Thin Margins and Governance Concerns

2026-02-07 23:45:37

Venmax Drugs & Pharmaceuticals Ltd., a micro-cap pharmaceutical company with a market capitalisation of just ₹25.00 crores, posted a net profit of ₹0.03 crores in Q3 FY26 (October-December 2025), marking a sequential increase of 50.00% from Q2 FY26's ₹0.02 crores. However, this modest absolute profit figure belies deeper structural concerns that continue to plague the Hyderabad-based company, including razor-thin operating margins, negative book value, and a dramatic decline in promoter holdings that has raised serious governance questions.

Read full news article

View All News